The Ebola virus breakout in Western Africa controlled much of the stories in 2014. The highly communicable virus spreads quickly and kills over half of those people who become infected, resulting in heavy panics across multiple continents. While the vast majority of the dead are in Africa, health employees did bring the pathogen home to other nations and continents.
For all of the doom and gloom and focus on doomsday scenarios on what the virus could do, there are actually dome economic benefits of Ebola virus break outs. The economic benefits mostly breakdown between non-profit or govt groups and for-profit biotechnology companies.
Executive or aid setups like the Red Cross or the CDC tend to see increases in funding in events like these. The economic benefits to them are direct and help out those on the ground suffering or helping and containing an onset.
This containment keeps commercial disruption when funding is acceptable to turn the tide of an outbreak.
The long term business benefits of Ebola virus onsets are biotech firms working on vaccines or medications that might improve survival rates of those infected with Ebola. One such firm is Tekmira, which has been given blessings by the FDA to expand testing on in its experimental Ebola drug for bigger scale controlled trials.
Sarepta Therapeutics, Nanoviricides and BioCryst Pharmaceuticals are other biotech outfits that might see increased business in the future if their own Ebola drugs and medications turn out to be of value.
While the 2014 Ebola breakout is first to have caught world attention as much as it did, it was hardly the first onset. Others have occurred, and more will happen in days to come. Any business that has an Ebola drug or vaccine on the market that proves effective can be sure to see an increase in business in the future.
For all of the doom and gloom and focus on doomsday scenarios on what the virus could do, there are actually dome economic benefits of Ebola virus break outs. The economic benefits mostly breakdown between non-profit or govt groups and for-profit biotechnology companies.
Executive or aid setups like the Red Cross or the CDC tend to see increases in funding in events like these. The economic benefits to them are direct and help out those on the ground suffering or helping and containing an onset.
This containment keeps commercial disruption when funding is acceptable to turn the tide of an outbreak.
The long term business benefits of Ebola virus onsets are biotech firms working on vaccines or medications that might improve survival rates of those infected with Ebola. One such firm is Tekmira, which has been given blessings by the FDA to expand testing on in its experimental Ebola drug for bigger scale controlled trials.
Sarepta Therapeutics, Nanoviricides and BioCryst Pharmaceuticals are other biotech outfits that might see increased business in the future if their own Ebola drugs and medications turn out to be of value.
While the 2014 Ebola breakout is first to have caught world attention as much as it did, it was hardly the first onset. Others have occurred, and more will happen in days to come. Any business that has an Ebola drug or vaccine on the market that proves effective can be sure to see an increase in business in the future.
About the Author:
my name is alfred obi I've been a biological scientist for years educating individuals on ebola virus disease update and ebola virus disease which has influenced most nations in africa feel free to visit my site for your free protecting gear on ebola thanks.
0 Response to "The Commercial Benefits Of Ebola Virus Outbursts"